illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Shanghai Fudan Zhangjiang Bio Pharmaceutical
Company logo

Shanghai Fudan Zhangjiang Bio Pharmaceutical | Sustainability Performance

http://www.fd-zj.com/desktopmodules/ht/English/Company/Index.aspx?LS=1

Conducts research, development, and production of biopharmaceutical products.

1996

China

51 - 200 employees

Pharmaceuticals

$25M - 100M in revenue

Not profitable

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#9060
Overall
#495
in China
#218
in Pharmaceuticals

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

260 out of 292

Overview
Governance
TargetsESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
BioKangtai

China, Health Care, Biotechnology


Company logo
China National Accord Medicines

China, Health Care, Pharmaceuticals


Company logo
Shandong Buchang Pharmaceuticals

China, Health Care, Pharmaceuticals

Market cap

8.3B $, 2026▼12.6% YoY

Revenue

709.0M $, 2024▲19.9% YoY

R&D intensity

40.2% 2024

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Market cap

8.3B $, 2026▼12.6% YoY

Revenue

709.0M $, FY2024▲19.9% YoY

EBITDA

58.0M $, FY2024▼9.1% YoY

Operating margin

2% Industry: -33▲633.9% YoY

P/E ratio

198.8 Industry: 26▼56% YoY

Revenue & EBITDA

$709.0MFY2024 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

-60.0M 2024▼53.3% YoY

Capex

43.0M 2024▲130.2% YoY

Debt/equity ratio

0.0 Industry: 0▼NaN% YoY

R&D intensity

40.2%FY2024

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Return on invested capital

2.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

1.0

2022

0.8

2023

0.7

2024

NaN


Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Not available

27%
Independent Directors

3 out of 11 incl. management

Powered by illuminem

Overall score

0

Environment

0

Social

0

Governance

0

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Not available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

Not committed to key sustainability initiatives

Sustainability employees


    Available in
    Scale package

    Access
  • Email

  • Email